LP
FULC icon

LMR Partners’s Fulcrum Therapeutics FULC Stock Holding History

LMR Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3K Buy
+5,000
New +$30.4K ﹤0.01% 1432

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's FULC Position: Q2 2026 in Review

LMR Partners held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 30,000 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

LMR Partners first reported a position in FULC in Q3 2021 and has held it in 8 quarters since. The position peaked at $846K in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • LMR Partners held 30,000 shares of Fulcrum Therapeutics worth $110K as of Q2 2026.
  • LMR Partners left its Fulcrum Therapeutics share count unchanged in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1367 holding.
  • LMR Partners first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • LMR Partners's Fulcrum Therapeutics position peaked at $846K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.